Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578

SANOFI

 (SAN)

1961
Real-time Quote. Real-time Tradegate - 05/17 03:59:59 pm
85.055 EUR   +0.51%
1d agoDJSANOFI: Could Exit Toulouse Site in 5 Years
1d ago SANOFI: announces the next steps of its Research site in Toulouse, France
1d ago France's ID Logistics eyes acquisitions in 2013
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisionsForum 
Sector
Healthcare
Biotechnology / Pharmaceuticals
 Biotechnology / Pharmaceuticals
  Pharmaceuticals - Diversified
Logo
Logo SANOFI
Business Summary
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (82.6%): for the treatment of cardio-vascular diseases, thrombosis, central nervous system disorders (insomnia, multiple sclerosis, epilepsy), cancers, allergies, etc. Moreover, Sanofi-Aventis markets OTC products and generic drugs;
- human vaccines (11.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas;
- veterinary products (6.2%).
At the end of 2012, the group had 112 production sites throughout the world.
Net sales are distributed geographically as follows: France (8.1%), Europe (23.5%), the United States (31.8%), and other (37.3%).
Surperformance© rating of SANOFI
Overall rating In sector In country
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Pharmaceuticals - Diversified
CountryTrading RatingInvestor Rating
JOHNSON & JOHNSONUSA
ROCHE HOLDING LTD.Switzerland
PFIZER INC.USA
NOVARTIS AGSwitzerland
SANOFIFrance
MERCK & CO., INC.USA
GLAXOSMITHKLINE PLCUnited Kingdom
BAYER AGGermany
NOVO NORDISK A/SDenmark
BRISTOL MYERS SQUIBB CO.USA
ELI LILLY & CO.USA
ABBOTT LABORATORIESUSA
TEVA PHARMACEUTICAL INDUSTRIES LIMITEDISRAEL
ALEXION PHARMACEUTICALS, INC.USA
SHIRE PLCUnited Kingdom
ACTAVIS INCUSA
DAIICHI SANKYO COMPANY, LIMITEDJapan
CHUGAI PHARMACEUTICAL CO., LTD.Japan
MYLAN INC.USA
UCBBelgium
BIOMARIN PHARMACEUTICAL INC.USA
TASLY PHARMACEUTICAL GROUP CO LTDCHINA
TAISHO PHARMACEUTICAL HOLDINGS CO LTDJapan
HISAMITSU PHARMACEUTICAL CO., INC.Japan
WARNER CHILCOTT PLCUSA
Sector Pharmaceuticals - Diversified
Data source :
© 2013 Thomson Reuters
Ratings :
© 2013 Surperformance
Shareholders
- L'Oréal 8,82%
- Total 2,83%
- Company-owned shares 1,28%
- Employees 1,38%
Advertisement
Managers
- Executive VP, Pharmaceutical Operations :
    Hanspeter Spek
- Chairman of the Board :
    Serge Weinberg
- Executive VP, Chief Financial Officer :
    Jérôme Contamine
- Chief Executive Officer :
    Christopher A. Viehbacher
- VP Investor Relations :
    Sébastien Martel
- Communications :
    Laure Thibaud
- Senior VP, Legal Affairs and General Counsel :
    Karen Linehan
- Senior VP, Industrial Affairs :
    Philippe Luscan
- Senior VP, Human Resources :
    Roberto Pucci
Company contact information
54 rue la Boétie
FR-75008 Paris
France

Phone : +33 (0)1 53 77 40 00
Fax : +33 (0)1 53 77 44 63
Internet : http://www.sanofi.com
Markets and indexes
- PEA / SRD eligible : YES / YES
- NYSE Euronext Paris
- Compartiment A
- CAC 40 / CAC All Shares, CAC All-Tradable, CAC Large 60, Euronext 100, EuroStoxx 50, Eurotop 100, Stoxx 50, Stoxx France 50, Stoxx Global 200
Stock Exchange Codes
- ISIN Code :  FR0000120578
- Bloomberg Code :  SAN:FP
- Reuters Code :  SASY.PA
- Datastream Code :  F:SQ@F
Financial data source :
© 2013 Cofisem
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.